296 results on '"Vignetti, M."'
Search Results
2. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT
3. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes
4. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
5. Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial
6. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
7. Supplement to: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
8. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine
9. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR–ABL1-positive acute lymphoblastic leukemia patients
10. Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
11. Analysis of p73 expression pattern in acute myeloid leukemias: lack of ΔN-p73 expression is a frequent feature of acute promyelocytic leukemia
12. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
13. Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols
14. Acute megakaryoblastic leukemia: experience of GIMEMA trials
15. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in Italy
16. IKZF1 (IKAROS) deletions represent a poor prognostic marker in BCR-ABL1 positive acute lymphoblastic leukaemia patients: a GIMEMA ALL WP report: O133
17. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials
18. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors
19. Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials
20. Myelodysplastic syndromes in childhood: description of seven cases
21. Results of autologous haemopoietic stem cell transplantation in very good risk patients with acute myelocytic leukaemia, supposedly not candidates for a transplant - an EBMT survey
22. Obesity and autologous stem cell transplantation in acute myeloid leukemia
23. PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED‐INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY.
24. P1706: CLINICAL UTILITY OF ONLINE MONITORING OF PATIENT‐REPORTED SYMPTOMS IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN REAL‐LIFE PRACTICE.
25. P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D‐ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL.
26. 251 TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK
27. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
28. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
29. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
30. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
31. A Proposed Clinical Trial Model: Analyzing the CT Process.
32. Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia.
33. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200?mg/m2).
34. Treatment of elderly patients (=60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.
35. 322 TET2 mutations, methylation profile and prognosis in higher risk myelodysplastic syndromes (MDS) treated with 5-azacytidine and valproic acid
36. 208 Iron chelation therapy with deferasirox in transfusion dependent myelodysplastic syndrome patients. Preliminary report from the prospective MDS0306 GIMEMA trial
37. 147 Involvement in treatment decisions, desire for prognostic information and quality of life in high-risk myelodysplastic syndromes: the physician's perspective
38. Use of Interleukin-2 in the Management of Haematological Malignancies: Focus on Minimal Residual Disease.
39. OP08 High dose (HD-AraC) vs standard dose cytosine arabinoside (SD-AraC) during induction in acute myelogenous leukemia (AML): Impact on stem cell mobilization after consolidation and on autologous transplantation (AML-12 trial)
40. Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).
41. Prognostic Impact of Genetic Characterization in the GIMEMA LAM99P Study for Newly Diagnosed Adult AML. Relevance of Combined Analysis of Conventional Karyotyping, FLT3 and NPM Mutational Status.
42. A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups.
43. Clinical Impact of Q-RT-PCR Monitoring of Minimal Residual Disease in Newly Diagnosed Adult Patients with BCR-ABL+ Acute Lymphoblastic Leukemia Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.
44. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience
45. Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: Neurological and electroencephalographic prospective study
46. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials -- a systematic review to evaluate the added value in supporting clinical decision making.
47. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
48. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200?mg/m2).
49. Interleukin 2 in the management of hematologic malignancies
50. Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.